Relation between behaviorally augmented tolerance and upregulation of muscarinic receptors in the CNS: Effects of chronic administration of scopolamine

1986 ◽  
Vol 88 (1) ◽  
pp. 33-39 ◽  
Author(s):  
Roger W. Russell ◽  
Frederick J. Ehlert ◽  
Joyce J. Hwa
Keyword(s):  
Muscarinic Receptors ◽  
Chronic Administration ◽  
Cns Effects ◽  
Behaviorally Augmented Tolerance

Alterations in β adrenergic and muscarinic receptors in aged rat heart. Effects of chronic administration of propranolol and atropine

1991 ◽  
Vol 60 (2) ◽  
pp. 215-224 ◽  
Author(s):  
B. Chevalier ◽  
P. Mansier ◽  
E. Teiger ◽  
F. Callens-El Amrani ◽  
B. Swynghedauw
Keyword(s):  
Muscarinic Receptors ◽  
Rat Heart ◽  
Chronic Administration ◽  
Aged Rat

1294: Quantitative Expression of Muscarinic Receptors in Urothelium and Detrusor of Healthy and Neurogenic Human Bladder

2006 ◽  
Vol 175 (4S) ◽  
pp. 417-417
Author(s):  
Shachi Tyagi ◽  
Naoki Yoshimura ◽  
Michael B. Chancellor ◽  
Fernando De Miguel
Keyword(s):  
Muscarinic Receptors ◽  
Human Bladder ◽  
Quantitative Expression

Exploring the CNS effects of acupuncture needling with TMS

2011 ◽  
Vol 44 (06) ◽  
Author(s):  
M Zunhammer ◽  
V Busch ◽  
J Franz ◽  
J Haas ◽  
P Eichhammer
Keyword(s):  
Cns Effects

Ridogrel Inhibits Systemic and Renal Formation of Thromboxane A2 and Antagonizes Platelet Thromboxane A2/Prostaglandin Endoperoxide Receptors upon Chronic Administration to Man

1992 ◽  
Vol 68 (02) ◽  
pp. 214-220 ◽  
Author(s):  
C Weber ◽  
J R Beetens ◽  
F Tegtmeier ◽  
P Van Rooy ◽  
E Vercammen ◽  
...  
Keyword(s):  
Uric Acid ◽  
Potent Inhibitor ◽  
Ex Vivo ◽  
Thromboxane A2 ◽  
Chronic Administration ◽  
Response Curves ◽  
Clinically Significant ◽  
Synthase Inhibitor ◽  
The Right ◽  
Steady State Plasma Level

SummaryThe effects of ridogrel, a dual thromboxane A2 (TXA2) synthase inhibitor and TXA2/prostaglandin (PG) endoperoxide receptor antagonist, on systemic and renal production of prostaglandins and on platelet TXA2/PG endoperoxide receptors was evaluated upon chronic administration (300 mg b. i. d. orally, for 8 and 29 days) to man. Such a medication with ridogrel inhibits the systemic as well as the renal production of TXA2 as measured by the urinary excretion of 2,3-dinor-TXB2 and TXB2 respectively without inducing significant changes in systemic or renal PGI2 production. Simultaneously with the latter effects, the production of TXB2 by spontaneously coagulated whole blood ex vivo is inhibited (>99%) while that of PGE2 and PGF2α is largely increased. Administration of ridogrel causes a three- to five-fold shift to the right of concentration-response curves for U46619 in eliciting platelet aggregation; no tachyphylaxis is observed after 29 days of treatment in this respect. Apart from a reduction of serum uric acid levels with a concomitant increase in urinary uric acid excretion during the first days of treatment, no clinically significant changes in hematological, biochemical, hemodynamic and coagulation parameters occur during the 8 days or 29 days study. The study demonstrates that ridogrel is a potent inhibitor of the systemic as well as renal TXA2 synthase and an antagonist of platelet TXA2/PG endoperoxide receptor in man, covering full activity during 24 h at steady-state plasma level conditions without tachyphylaxis during 29 days of medication. The compound is well tolerated, at least during 1 month of administration.

Sign in / Sign up

Export Citation Format

Share Document